MyoKardia Appoints William Fairey as Chief Commercial Officer
January 23 2019 - 8:30AM
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical
company pioneering a precision medicine approach for the treatment
of heritable cardiovascular diseases, today announced the
appointment of William C. Fairey as Chief Commercial Officer and
Executive Vice President. Mr. Fairey will have global
responsibility for oversight of all aspects of commercial
operations and serve as a key member of MyoKardia’s executive
leadership team.
“Bill is a leader with a strong and relevant
track record in building mission-driven, high-performing teams that
have brought important therapies to patients with few if any
options,” said Tassos Gianakakos, Chief Executive Officer of
MyoKardia. “His experience in market development, organizational
growth, and commercial execution in the US and internationally make
him ideally suited to lead MyoKardia’s commercial efforts.
We’re excited to have a global commercial leader of Bill’s caliber
join our team as we prepare for the potential launch of mavacamten
for the treatment of hypertrophic cardiomyopathy and advance our
growing portfolio of novel therapeutics into late-stage
studies.”
Mr. Fairey has nearly three decades of
biopharmaceutical industry experience building and leading
patient-focused and science-driven organizations. Most
recently, he served as the Chief Operating Officer and Executive
Vice President of ChemoCentryx, Inc., where he led the company’s
commercial strategy, including the development and execution of
commercialization plans for avacopan and CCX140. Prior to
ChemoCentryx, Mr. Fairey held global leadership positions with
Actelion Pharmaceuticals over a period of seventeen years, most
recently serving as President of Actelion Pharmaceuticals U.S.
Inc., overseeing more than 400 employees and $1.5 billion in net
sales in 2017 before its acquisition by Johnson & Johnson for
$30 billion. At Actelion US, he helped the company gain FDA
approvals and launch OPSUMIT and UPTRAVI for pulmonary arterial
hypertension and VALCHLOR for cutaneous T-cell lymphoma.
Mr. Fairey also served as President of Actelion
Canada and as Regional Vice President of Australia Asia Pacific,
where he had oversight across the region, including founding
Actelion’s first affiliates in China, Taiwan and Singapore.
Before taking on the Canadian role, Mr. Fairey was Vice President
of Sales and Managed Markets in the US, where he built Actelion’s
first sales and managed markets teams and established the
strategies and systems to support the launch of Actelion’s first
product, TRACLEER. Before joining Actelion, Mr. Fairey held a
number of commercial roles during his 12 years with Parke-Davis
Pharmaceuticals US.
“I was drawn to MyoKardia’s mission, innovative
scientific approach and portfolio of high-quality and wholly-owned
candidates in all stages of development,” said Mr. Fairey.
“MyoKardia’s portfolio of potential targeted cardiovascular
therapies, including mavacamten, represent important new advances
in areas that have not seen therapeutic innovation in
decades. I look forward to engaging with MyoKardia’s
dedicated and driven team in bringing innovative treatments to
patients and families with serious cardiovascular diseases.”
Mr. Fairey holds a bachelor’s degree in Biology
from the University of Oregon and earned a Master of Business
Administration degree from Saint Mary’s College of California.
About MyoKardia MyoKardia is a
clinical-stage biopharmaceutical company pioneering a precision
medicine approach to discover, develop and commercialize targeted
therapies for the treatment of serious and rare cardiovascular
diseases. MyoKardia’s initial focus is on the development of small
molecule therapeutics aimed at the cardiac muscle proteins that
modulate cardiac muscle contraction and underlie diseases of
systolic and diastolic dysfunction. Based on an in-depth
understanding of disease biology, MyoKardia applies a precision
medicine approach to develop its therapeutic candidates for patient
populations with shared characteristics, such as causal genetic
mutations or disease subtypes. MyoKardia’s most advanced product
candidate is mavacamten (formerly MYK-461), a novel, oral,
allosteric modulator of cardiac myosin intended to reduce
hypercontractility. Mavacamten has advanced into a pivotal Phase 3
clinical trial, known as EXPLORER-HCM in patients with symptomatic,
obstructive hypertrophic cardiomyopathy (HCM). MyoKardia is also
developing mavacamten in a second indication, non-obstructive HCM,
in the Phase 2 MAVERICK-HCM clinical trial. MYK-491, MyoKardia’s
second product candidate, is designed to increase cardiac output
among patients with systolic heart dysfunction by increasing the
overall extent of the heart’s cardiac contractility. MyoKardia is
currently evaluating MYK-491 in a Phase 1b/2a study in stable heart
failure patients.
MyoKardia’s mission is to change the world for
patients with serious cardiovascular disease through bold and
innovative science.
Forward-looking
StatementStatements we make in this press release may
include statements which are not historical facts and are
considered forward-looking within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are usually
identified by the use of words such as "anticipates," "believes,"
"estimates," "expects," "intends," "may," "plans," "projects,"
"seeks," "should," "will," and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including statements
regarding the clinical and therapeutic potential of mavacamten and
the potential launch of mavacamten, reflect our current views about
our plans, intentions, expectations, strategies and prospects,
which are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects as reflected in
or suggested by those forward-looking statements are reasonable, we
can give no assurance that the plans, intentions, expectations or
strategies will be attained or achieved. Furthermore, actual
results may differ materially from those described in the
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control including, without
limitation, risks associated with the development and regulation of
our product candidates, as well as those set forth in our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2018, and
our other filings with the SEC. Except as required by law, we
assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Michelle Corral
Senior Director, Corporate Communications and Investor Relations
MyoKardia, Inc.
650-351-4690
ir@myokardia.com
Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com
Steven Cooper (media)
Edelman
415-486-3264
steven.cooper@edelman.com
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Sep 2023 to Sep 2024